Protocol Ledger

NCT06363994 · Phase III · RECRUITING

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Interventional Phase III clinical trial protocol NCT06363994 sponsored by InnoCare Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-29 Enrollment: 476 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06363994
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)476 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06363994
Protocol FieldVerified Registry Value
NCT IdentifierNCT06363994
Consolidated Lead SponsorInnoCare Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment476 participants (ESTIMATED)
Registered Start Date2024-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06363994
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Sichuan Provincial People's HospitalChengdu, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI